Close Menu

About GenomeWeb Premium

Only GenomeWeb Premium Gives You the Full Story!

GenomeWeb Premium provides exclusive, in-depth coverage of the latest genomic and genetic technologies, life science research trends, and key issues in molecular diagnostics. Premium subscribers get the best of GenomeWeb's original reporting and are able to track the topics of most interest to them.

Premium membership offers unrestricted access across the entire GenomeWeb site. This includes any article featuring the GenomeWeb Premium icon: 

Premium subscribers can opt into any of our weekly topical mailings, which include:

  • Molecular Diagnostics
  • Cancer
  • Sequencing Technology
  • PCR
  • Informatics
  • Proteomics & Protein Research

Questions? Please contact [email protected] for further information.

Terms of Service for GenomeWeb Premium Licenses

All GenomeWeb content is protected by US and International copyright laws, and may not be copied, reprinted, published, translated, hosted, or otherwise distributed by any means without explicit permission.

Password sharing and redistribution of content are violations of the GenomeWeb Premium license agreement and are monitored. All Premium license users must log in with their own individual work email addresses. Premium users may not store premium articles on an internal or external web page accessible to other users, nor may they email full text or partial text articles to anyone inside or outside the subscribing organization without prior permission of GenomeWeb.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.